ERCC-1、survivin表达与含顺铂方案一线化疗治疗晚期肺腺癌患者疗效和预后关系

目的分析晚期肺腺癌患者组织中错配切除修复蛋白(excisition repair cross complement-1,ERCC-1)、凋亡抑制蛋白survivin表达同含顺铂方案一线化疗疗效和生存时间之间的关系。方法收集1999年1月~2005年12月在本院接受含顺铂方案一线化疗的、病理确诊为晚期肺腺癌患者的腊块80例。采用免疫组化方法检测ERCC-1、survivin的表达,并同化疗疗效和生存时间进行比较。结果共有77例可以评价染色,ERCC-1阳性率为33.77%,survivin阳性率为53.25%。ERCC-1阳性表达患者一线化疗有效率低,并且TTP和PFS较短,survivin阳性表达患者生存较差。结论ERCC-1阳性同晚期肺腺癌含顺铂方案一线化疗耐药和预后不良相关,survivin阳性表达提示晚期肺腺癌预后不良。

Relationship between Expression of ERCC-1, survivin and both Efficiency and Prognosis of Cisplatin-contained First-line Chemotherapy in Advanced Lung Adenocarcinoma

Objective 　To analyze the relationship between expression of ERCC21 (excisition repair cross complement21) 、survivin and sensitivity and prognosis of cisplatin2contained regimens first2line chemo2 therapy in advanced lung adenocarcinoma. Methods 　IHC was used to evaluate expression of ERCC21 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patient s given cisplatin2contained regimens first2line chemotherapy. The response rate and survival time were analyzed according to the ex2 pression of ERCC21 and survivin. Results 　Only 77 patient s could be reviewed by IHC staining. The ex2 pression rates of ERCC21 and survivin were 33. 77 % and 53. 25 % respectively. The worse response rate and shorter TTP/ PFS could be identified in ERCC21 positive group. Patient s with positive expression of survivin had worse survival time. Con2 clusion 　Expression of ERCC21 may be a molecular marker of cisplatin2con2 tained regimens first2line chemothera2 py resistance and poor prognosis in ad2 vanced lung adenocarcinoma patient s.Simiary expression of survivin predicates poor prognosis forpatient s with advanced lung adenocarcinoma.